Trump Administration Rule Paves Way For Association Health Plans
Proponents say the proposed regulation will give some consumers more affordable insurance options. Critics warn that the coverage could be less comprehensive.
Arthritis Drugs Show How U.S. Drug Prices Defy Economics
Drugs that treat rheumatoid arthritis started out costing about $10,000 a year. Ten years later, they list for more than $40,000.
Biosimilars, Biologics And New Legal Challenges For RA Treatments
As biosimilar products reach the market and rival more established RA treatments, the players are exploring legal challenges involving antitrust and anti-competitive behavior.
Consumers Who Froze Their Credit Reports Could Hit A Glitch Enrolling In Insurance
The federal marketplace generally uses credit reports to help verify identities, but that doesn’t work if consumers have put a security freeze on them — as some did after the Equifax breach this year. Workarounds for this issue exist, but they make the process more time-consuming.
Brokers Tout Mix-And-Match Coverage To Avoid High-Cost ACA Plans
But buyer, beware. Cobbling together “packages” designed to cover gaps in high-deductible health plans could shortchange consumers, warn advocates.
Desperate For Coverage: Are Short-Term Plans Better Than None At All?
As stopgap health plans gain attention as possible alternatives to Obamacare, consumers are advised to read the fine print.
Obamacare: confusión abre la puerta a planes de salud “sospechosos”
Los promocionan como una alternativa económica a los planes de ACA. Pero expertos en mercados de seguros dudan sobre el tipo de cobertura que ofrecen.
Marketplace Confusion Opens Door To Questions About Skinny Plans
Regulators are beginning to scrutinize claims by companies that their alternative plans help people meet Obamacare requirements.
Brokers Are Reluctant Players In A Most Challenging ACA Open-Enrollment Season
With federal support slashed for organizations that provided consumers help in making their health plan choices, insurance brokers have to pick up the slack.
Obamacare: 5 nuevas cosas que debes saber
El período abierto de inscripción para las personas que compran su propio seguro de salud ya está en marcha, y termina el 15 de diciembre de 2017. Estos son cinco factores para tener en cuenta.
5 Things To Know About ACA At Year 5
This year’s Obamacare open enrollment will be marked by a number of changes. KHN helps you navigate them.
Trump actuando solo: lo que debe saber sobre los cambios a la ley de salud
Las medidas del presidente Donald Trump eliminan los reembolsos a las aseguradoras, pero no los subsidios que permiten a los consumidores pagar sus primas.
Trump Acting Solo: What You Need To Know About Changes To The Health Law
A quick guide to revisions to the cost-sharing subsidies for lower-income marketplace customers and the proposal to add different plans to the market.
Trump’s Order Advances GOP Go-To Ideas To Broaden Insurance Choices, Curb Costs
But the approaches are not new and critics worry that these changes will leave some consumers with skimpier plans that expose them to high medical bills.
Association Health Plans: A Favorite GOP Approach To Coverage Poised For Comeback
Both President Donald Trump and Sen. Rand Paul (R-Ky.) signaled last week that executive action was in the works that would give these plans a boost.
Tragedia de Las Vegas plantea la capacidad de un hospital para atender a las víctimas
En la ciudad hay un solo centro de trauma, especializado en tratar a pacientes con lesiones severas producto de disparos, caídas o accidentes automovilísticos. Qué pasa a nivel nacional
Las Vegas Faced a Massacre. Did It Have Enough Trauma Centers?
Hospitals view adding trauma care as a potential profit tool, but experts say having more centers does not necessarily improve the system’s ability to respond to a mass casualty event.
Vital Health Officials You’ve Never Heard Of: Insurance Commissioners In The Hot Seat
The fate of the Affordable Care Act’s individual insurance marketplaces remains in play as state insurance commissioners take a central role in the debate.
Denial, Appeal, Approval … An Adult’s Thorny Path To Spinraza Coverage
The FDA granted approval for Spinraza in late December for use on children and adults with spinal muscular atrophy. Insurance coverage is mostly focused on infants and children.
Drug Puts A $750,000 ‘Price Tag On Life’
The high cost of Spinraza, a new and promising treatment for spinal muscular atrophy, highlights how the cost-benefit analysis insurers use to make drug coverage decisions plays out in human terms.
